您当前的位置：

RIPA-56

目录号: PL11037 纯度: ≥99%

RIPA-56 是一种高效选择和代谢稳定的受体相互作用蛋白 1 (RIP1) 抑制剂，IC50 为 13 nM。RIPA-56 可用于研究全身炎症反应综合征。

CAS No. :1956370-21-0

商品编号	规格	价格	会员价
PL11037-10mg	10mg	¥1680.00	请登录
PL11037-50mg	50mg	¥6247.50	请登录
PL11037-100mg	100mg	¥4259.00	请登录
PL11037-200mg	200mg	¥7473.00	请登录
PL11037-500mg	500mg	询价	询价
PL11037-1g	1g	询价	询价
PL11037-10mM*1mLinDMSO	10mM*1mLinDMSO	¥972.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	RIPA-56
英文名称	RIPA-56
英文别名	RIPA-56;RIPA56;N-Benzyl-N-hydroxy-2,2-dimethylbutanamide
Cas No.	1956370-21-0
分子式	C₁₃H₁₉NO₂
分子量	221.30
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	RIPA-56 是一种高效选择和代谢稳定的受体相互作用蛋白 1 (RIP1) 抑制剂，IC₅₀ 为 13 nM。RIPA-56 可用于研究全身炎症反应综合征。
生物活性	RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) with an IC 50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome.
性状	Solid
IC50 & Target[1][2]	IC50: 13 nM (RIP1)
体外研究(In Vitro)	RIPA-56 shows efficient inhibition of RIP1 kinase activity, with an IC50 of 13 nM and no inhibition of RIP3 kinase activity at a 10 μM concentration. RIPA-56 also demonstrates potency in protection of murine L929 cells from TNFα/z-VAD-FMK (TZ)-induced necrosis (EC50=27 nM). has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)	In the SIRS mice disease model, RIPA-56 efficiently reduces tumor necrosis factor alpha (TNFα)-induced mortality and multi-organ damage. Compared to known RIP1 inhibitors, RIPA-56 is potent in both human and murine cells, is much more stable in vivo, and is efficacious in animal model studies. RIPA-56 has an impressive PK profile in mice with a 3.1 h half-life, 22% oral bioavailability (P.O.), and 100% bioavailability from intraperitoneal injection (I.P.). has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Ren Y, et al. Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-InteractingProtein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome. J Med Chem. 2017 Feb 9;60(3):972-986.

溶解度数据	In Vitro: DMSO : ≥ 100 mg/mL (451.88 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

RIPA-56

相关产品

The molarity calculator equation

The dilution calculator equation